Evidence map›Paper›PMID 42053152›Full record

ArticleCancer science2026

Population-Based Identification of Clonal Hematopoiesis Using Peripheral Blood Whole-Genome Sequencing in Japan.

SungGi Chi, Ikuko N Motoike, Takao Fujisawa, Yumi Yamaguchi-Kabata, Takahiro Nobukuni, Kengo Kinoshita, Yoshiaki Nakamura, Hideaki Bando, Takayuki Yoshino, Kinuko Ohneda and 3 more

Abstract read
In one paragraph

Article in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

SungGi ChiNational Cancer Center Hospital East, Kashiwa, Japan.ORCID https://orcid.org/0000-0002-5725-7187
Ikuko N MotoikeTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Takao FujisawaNational Cancer Center Hospital East, Kashiwa, Japan.
Yumi Yamaguchi-KabataTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Takahiro NobukuniTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Kengo KinoshitaTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Yoshiaki NakamuraNational Cancer Center Hospital East, Kashiwa, Japan.ORCID https://orcid.org/0000-0002-5241-6855
Hideaki BandoNational Cancer Center Hospital East, Kashiwa, Japan.ORCID https://orcid.org/0000-0001-5041-2765
Takayuki YoshinoNational Cancer Center Hospital East, Kashiwa, Japan.ORCID https://orcid.org/0000-0002-0489-4756
Kinuko OhnedaTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Katsuya TsuchiharaDivision of Translational Informatics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.ORCID https://orcid.org/0000-0001-7507-2349
Yosuke MinamiNational Cancer Center Hospital East, Kashiwa, Japan.ORCID https://orcid.org/0000-0003-0863-0739
Riu YamashitaDivision of Translational Informatics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.

Funding

Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS) 23K14637
6 · The paper itself

Abstract

Clonal hematopoiesis of indeterminate potential (CHIP) is an age-associated condition whose population-level characteristics and clinical concordance in Japan remain incompletely defined. We analyzed whole-genome sequencing data from 49,982 participants in the Tohoku Medical Megabank (TMM) cohort to characterize the prevalence, mutational spectrum, age dependency, and clinical relevance of CHIP. CHIP mutations were detected in 1234 individuals (2.5%), comprising 1413 variants across 1015 loci. DNMT3A and TET2 were the most frequently mutated genes, whereas ASXL1 and PPM1D mutations were less prevalent than reported in Western cohorts. Four recurrent CHIP candidate loci (ZNF318, SMC3, CBL, and GNAS) were identified, most of which were predicted to be oncogenic. Comparison with TOPMed and UK Biobank datasets demonstrated overall concordance in variant prevalence, with differences observed for selected driver mutations. dN/dS analysis indicated positive selection in the majority of CHIP-associated genes. Concordance with clonal hematopoiesis (CH) mutations detected in cancer patients was evaluated using data from the MONSTAR-SCREEN-2 study with paired leukocyte sequencing. When focusing on genes in which CHIP mutations have been reported, 66% were confirmed as CH, yielding a positive predictive value of 66% and a negative predictive value of 76%. CHIP prevalence increased significantly with age, exceeding 5% in individuals aged ≥ 70 years, with an estimated 3.4% increase per additional year of age. Higher variant allele frequency mutations showed a slightly stronger age association. These findings define the landscape of CHIP in the Japanese population and clarify its relationship to CH detected by cancer-focused liquid biopsy assays.

Indexed as

Clonal HematopoiesisWhole Genome SequencingAdultAgedAged, 80 and overDioxygenasesDNA-Binding ProteinsDNA Methyltransferase 3AFemaleHumansJapanMaleMiddle AgedMutationDioxygenasesDNA-Binding ProteinsDNA Methyltransferase 3Aclonal hematopoiesis of indeterminate potentialcohort study of japanese residentscomprehensive genomic profilinggenomic databasewhole‐genome sequencing

Identifiers

PMID42053152
PMCPMC13327082

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.